BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)

BACKGROUND: Despite adequate trans-urethral resection of the bladder tumour (TURBT), non-muscle-invasive bladder cancer (NMIBC) is associated with high rates of recurrence and progression. Instillation of Bacillus Calmette-Guérin (BCG) into the urinary bladder after TURBT (adjuvant intravesical admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayne, Dickon, Stockler, Martin, McCombie, Steve P., Chalasani, Venu, Long, Anne, Martin, Andrew, Sengupta, Shomik, Davis, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445809/
https://www.ncbi.nlm.nih.gov/pubmed/26014129
http://dx.doi.org/10.1186/s12885-015-1431-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445809/
https://www.ncbi.nlm.nih.gov/pubmed/26014129
http://dx.doi.org/10.1186/s12885-015-1431-6

Ejemplares similares